At HLTH Europe 2025 in Amsterdam, pharmaphorum Deep Dive editor Eloise McLennan sat down with Eugene Borukhovich (CEO, YourCoach Health), David Klein (CEO, Click Therapeutics), and Malin Johansson ...

In Part Two, putting theory into practice is addressed.

Researchers at the University of Arizona recently studied a non-invasive technique that uses sound waves to stimulate ...

The reduction in Bayer's workforce under turnaround chief executive Bill Anderson has reached around 12,000 – a fall of ...

A jury in the US has found that tech giant Meta illegally compromised the privacy of a US woman who shared her data with a ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

The joint information sharing agreement between the medicines regulatory authority and reimbursement agency was first ...

US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has said he will cut $500 million in funding for mRNA ...

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

Explore the latest pharmaceutical trends and predictions for 2025 from an incoming CEO's perspective. Stay ahead of the curve and prepare your organisation for the future.

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...

The journey of medicinal cannabis has seen remarkable adoption worldwide. Once marginalised and stigmatised, cannabis is now making its way into the mainstream of medicine and healthcare, offering ...